OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 13,597 AbbVie Inc. $ABBV

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,597 shares of the company's stock, valued at approximately $3,416,000.

Several other institutional investors have also recently made changes to their positions in the stock. August Group Capital Ltd purchased a new position in shares of AbbVie during the 2nd quarter valued at about $871,000. E Fund Management Co. Ltd. bought a new stake in AbbVie during the 2nd quarter worth approximately $5,751,000. Pasadena Private Wealth LLC purchased a new position in AbbVie during the second quarter valued at approximately $494,000. Notis McConarty Edward purchased a new position in AbbVie during the second quarter valued at approximately $3,734,000. Finally, Asahi Life Asset Management CO. LTD. bought a new position in shares of AbbVie in the second quarter worth approximately $1,098,000. Institutional investors own 70.23% of the company's stock.

Analysts Set New Price Targets

ABBV has been the topic of several recent analyst reports. HSBC restated a "buy" rating and set a $300.00 price objective on shares of AbbVie in a research report on Monday, July 6th. Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research report on Wednesday, July 15th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Finally, Piper Sandler boosted their price target on AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $275.95.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company's stock.

AbbVie Trading Up 0.2%

Shares of ABBV stock opened at $256.08 on Monday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The stock's 50-day moving average price is $252.66 and its 200-day moving average price is $228.91. The stock has a market capitalization of $452.44 billion, a price-to-earnings ratio of 72.34, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The firm's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source